Plain-English translation of NCT06999798 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing a new ultrasound twinkling marker—a tiny device designed to make it easier for doctors to see cancer-affected lymph nodes on ultrasound. The marker is placed directly into the affected lymph node and is meant to stay visible on imaging for months, helping surgeons locate and remove the right tissue during surgery.
Currently, standard biopsy markers used to mark cancer in lymph nodes are hard to see on ultrasound about 25% of the time. This new treatment aims to solve that problem by using a special ultrasound technique that makes the marker much easier to spot, so surgeons can confidently find and remove the cancer-affected lymph node.
You likely qualify if…
You likely don't qualify if…
You will have the ultrasound twinkling marker placed into your affected lymph node using ultrasound guidance. You'll then have imaging (ultrasound and mammography) before starting any cancer treatment, and optional ultrasound scans during treatment as needed. Finally, during your planned surgery to remove the cancer-affected lymph node, the surgeon will remove the marker along with the tissue. The entire process is part of your regular cancer care.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States